Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity - PubMed (original) (raw)
Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity
Andrea Jegerlehner et al. J Immunol. 2004.
Abstract
Vaccination of mice with a peptide corresponding to the extracellular part of M2 protein coupled to the immunodominant domain of hepatitis B core can protect mice from a lethal challenge with influenza A virus. As the extracellular part of M2 protein is highly conserved in all known human influenza A strains, such a vaccine may protect against all human influenza A strains, which would represent a major advantage over current vaccine strategies. The present study demonstrates that protection is mediated exclusively by Abs, a very important feature of a successful preventive vaccine. However, these Abs neither bind efficiently to the free virus nor neutralize virus infection, but bind to M2 protein expressed on the surface of virus-infected cells. The presence of NK cells is important for protection, whereas complement is not, supposing that protection is mediated via Ab-dependent, cell-mediated cytotoxicity. The absence of neutralizing Abs results in much weaker protection than that achieved by vaccination with UV-inactivated influenza virus. Specifically, whereas neutralizing Abs completely eliminate signs of disease even at high viral challenge doses, M2-specific Abs cannot prevent infection, but merely reduce disease at low challenge doses. M2-specific Abs fail to protect from high challenge doses, as vaccinated mice undergo lethal infection under these conditions. In conclusion, protection mediated by M2-hepatitis B core vaccine would be insufficient during the yearly epidemics, for which full protection is desirable, and overall is clearly inferior to protection achieved by immunization with classical inactivated viral preparations.
Similar articles
- Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus.
Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi ATJ. Heinen PP, et al. J Gen Virol. 2002 Aug;83(Pt 8):1851-1859. doi: 10.1099/0022-1317-83-8-1851. J Gen Virol. 2002. PMID: 12124449 - Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.
Mozdzanowska K, Zharikova D, Cudic M, Otvos L, Gerhard W. Mozdzanowska K, et al. Virol J. 2007 Oct 31;4:118. doi: 10.1186/1743-422X-4-118. Virol J. 2007. PMID: 17974006 Free PMC article. - Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
Kim YJ, Kim KH, Ko EJ, Kim MC, Lee YN, Jung YJ, Lee YT, Kwon YM, Song JM, Kang SM. Kim YJ, et al. J Virol. 2018 Sep 26;92(20):e00969-18. doi: 10.1128/JVI.00969-18. Print 2018 Oct 15. J Virol. 2018. PMID: 30068650 Free PMC article. - Vaccine options for influenza: thinking small.
Schepens B, De Vlieger D, Saelens X. Schepens B, et al. Curr Opin Immunol. 2018 Aug;53:22-29. doi: 10.1016/j.coi.2018.03.024. Epub 2018 Apr 7. Curr Opin Immunol. 2018. PMID: 29631195 Review. - Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S, Ainai A, Suzuki T, Kurata T, Hasegawa H. Tamura S, et al. Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Jpn J Infect Dis. 2016. PMID: 27212584 Review.
Cited by
- A Human Anti-M2 Antibody Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Cytokine Secretion by Resting and Cytokine-Preactivated Natural Killer (NK) Cells.
Simhadri VR, Dimitrova M, Mariano JL, Zenarruzabeitia O, Zhong W, Ozawa T, Muraguchi A, Kishi H, Eichelberger MC, Borrego F. Simhadri VR, et al. PLoS One. 2015 Apr 27;10(4):e0124677. doi: 10.1371/journal.pone.0124677. eCollection 2015. PLoS One. 2015. PMID: 25915748 Free PMC article. - Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.
Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, Cheon IS, Joo DH, Cho CH, Song MS, Seo SU, Byun YH, Park HJ, Poo H, Seong BL, Kim JO, Nguyen HH, Stadler K, Kim DW, Hong KJ, Czerkinsky C, Song MK. Shim BS, et al. PLoS One. 2011;6(11):e27953. doi: 10.1371/journal.pone.0027953. Epub 2011 Nov 30. PLoS One. 2011. PMID: 22140491 Free PMC article. - Prospects and Challenges in the Development of Universal Influenza Vaccines.
Madsen A, Cox RJ. Madsen A, et al. Vaccines (Basel). 2020 Jul 6;8(3):361. doi: 10.3390/vaccines8030361. Vaccines (Basel). 2020. PMID: 32640619 Free PMC article. Review. - Virus-like particles as universal influenza vaccines.
Kang SM, Kim MC, Compans RW. Kang SM, et al. Expert Rev Vaccines. 2012 Aug;11(8):995-1007. doi: 10.1586/erv.12.70. Expert Rev Vaccines. 2012. PMID: 23002980 Free PMC article. Review. - Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques.
Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ. Jegaskanda S, et al. J Virol. 2013 May;87(10):5512-22. doi: 10.1128/JVI.03030-12. Epub 2013 Mar 6. J Virol. 2013. PMID: 23468501 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials